Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Receivables: 2017-2025

  • Dr Reddys Laboratories' Receivables rose 9.87% to $1.1 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $3.8 billion, marking a year-over-year increase of 11.13%. This contributed to the annual value of $1.1 billion for FY2025, which is 9.87% up from last year.
  • Dr Reddys Laboratories' Receivables amounted to $1.1 billion in Q1 2025, which was up 9.87% from $963.0 million recorded in Q1 2024.
  • Dr Reddys Laboratories' 5-year Receivables high stood at $1.1 billion for Q1 2025, and its period low was $679.0 million during Q1 2021.
  • In the last 3 years, Dr Reddys Laboratories' Receivables had a median value of $963.0 million in 2024 and averaged $967.7 million.
  • Data for Dr Reddys Laboratories' Receivables shows a peak YoY rose of 29.60% (in 2022) over the last 5 years.
  • Dr Reddys Laboratories' Receivables (Quarterly) stood at $679.0 million in 2021, then climbed by 29.60% to $880.0 million in 2022, then increased by 0.23% to $882.0 million in 2023, then increased by 9.18% to $963.0 million in 2024, then climbed by 9.87% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q1 2025, $963.0 million for Q1 2024, and $882.0 million during Q1 2023.